← All trials
NCT06745531
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 13, 2025
- Primary completion
- Dec 23, 2025
- Completion date
- Dec 30, 2025
- First posted
- Dec 20, 2024
- Last posted
- Dec 20, 2024
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Taisho PharmaceuticalLead sponsor
- Taisho PharmaceuticalOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.